

Charity registration number: 1152445

Wolfram Syndrome UK

Annual Report and Financial Statements

for the Year Ended 28 February 2026

Streets (West Sussex) Limited
Wiston House
1 Wiston Avenue
Worthing
West Sussex
BN14 7QL

Wolfram Syndrome UK

Contents

Reference and Administrative Details	1
Trustees' Report	2 to 7
Statement of Trustees' Responsibilities	8
Independent Examiner's Report	9
Statement of Financial Activities	10 to 11
Balance Sheet	12
Notes to the Financial Statements	13 to 24

Wolfram Syndrome UK

Reference and Administrative Details

Chairman	Mr J Isherwood
Trustees	Mr A Nye Prof T Barrett Mr P Lynch Mr J Isherwood Miss A Gardner
Senior Management / Leadership Team	Mrs T Lynch, Chief Executive Dr G Isherwood PhD, Contracts Manager
Charity Registration Number	1152445
Registered Office	The charity is incorporated in England and Wales. 9 Church Way Tarring Worthing West Sussex BN13 1HD
Independent Examiner	Streets (West Sussex) Limited Wiston House 1 Wiston Avenue Worthing West Sussex BN14 7QL

Wolfram Syndrome UK

Trustees' Report

The trustees, who are directors for the purposes of company law, present the annual report together with the financial statements and auditors' report of the charitable company for the year ended 28 February 2026.

Objectives and activities

Objects and aims

Wolfram Syndrome (WS) is a genetic disorder causing Diabetes Insipidus, Diabetes Mellitus, optic atrophy and deafness. It affects children and adults and there is currently no known cure. There are currently around 143 people diagnosed with WS in the UK. This number is rising and expected to reach 170 due to increased genetic testing and improvements in the diagnosis of Wolfram Related Syndrome. WSUK exists to meet the needs of the WS community – the children, young people and adults affected by WS and their families. Due to the rare and under-researched nature of this illness, diagnosis currently takes 3-6 months and involves several thousand tests. There is only one recognised centre of expertise for children, which is at Birmingham Children's Hospital (BCH); and for adults, at Queen Elizabeth Hospital (QEH) Birmingham; therefore, it is believed that many cases may not be recognised.

WSUK raises funds to help finance further research and through its e-newsletters, website and annual conference increase levels of awareness, knowledge and understanding of this illness. These activities benefit not only those currently affected but also those diagnosed in the future and their families, not least in sustaining an enhanced national focus on finding effective treatments and an eventual cure.

For those currently affected and their families, WSUK maintains a voluntary register and distributes information about its aims, objectives and activities. WSUK provides direct and practical benefit through information, on-going front-line support, advice and guidance including at the WS multi-disciplinary clinics at BCH. Further practical and emotional benefit is provided by WSUK to families living with WS in the form of an annual conference, activities / projects for specific members of the WS community (e.g. WS affected adults) and virtual or in person family / community meetings.

As it is important for the WS community to have opportunities to meet in between the annual conferences, WSUK aims to provide social events that enable members of the WS community build relationships and provide peer support in a safe and welcoming space. This may include regular on-line sessions for small groups, and / or in person events or family days at venues around the country. It is intended that WSUK in person events are organised at little or no cost for families and individuals to help maximise participation. In addition, WSUK will aim to organise "take a break" opportunities for parents and carers at an affordable cost.

For the benefit of current and future WS affected people the level of awareness, debate and research among the public and within the professional community of medical practitioners is raised through a number of dissemination activities organised through WSUK. From the professional forums initially organised at the Birmingham clinics, WSUK will be able to identify potentially valuable research opportunities that it can support through its family network and financially. The WSUK website is also used to further disseminate research results and publications.

All these activities are aimed at benefiting all families registered with WSUK without any further restriction and regardless of their ability to contribute financially. At the discretion of the trustee's, financial support will be provided where poverty is a barrier to benefit. There will be no private benefits to anyone from WSUK other than as a beneficiary of its stated aims and activities.

No detriment or harm will arise from carrying out any of the aims, objectives or activities of WSUK.

Wolfram Syndrome UK

Trustees' Report

Public benefit

The trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning future activities.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Achievements and performance

WS Community Support

During 2025/2026, WSUK continued to provide expert support activities and services to the WS community, specifically through the following: -

1. Contract with Birmingham Women's and Children's NHS Foundation Trust (BWC NHSFT) to support the WS clinic services for children and young people.

In October 2025, WSUK successfully completed the third year of its contract with BWC NHSFT to support the WS Multi-Disciplinary Team (MDT) clinic services, part of the NHS England Highly Specialised Service, provided to affected children / young people (YP), and their parent carers and wider family members.

At the end of Y3 (i.e. Sep 2025), the WSUK Family Support Co-ordinators (FSCs) were either supporting or were actively engaged with the majority of the 53 YP and 48 families, targeted for support. During Y3, the FSCs had delivered or were delivering a total of 153 support issues (e.g. providing emotional support to parents), which represents an increase of +33% compared with Y2.

By the end of Y3, the FSCs had also successfully supported the four WS MDT clinics at BCH, which were attended by a total of 24 YP and their families, and were due to support two virtual clinics for 6 YP in Nov 2025 (part of Y4). In addition, in July 2025, the FSCs supported 5 YP at the WS MDT transition clinic at the Queen Elizabeth Hospital (QEH), which represents the first WS adult clinic that YP attend following their transfer from the WS paediatric service at BCH.

Some of WSUK's on-going activities conducted to support or inform the WS community, continue to form part of the contract BWC NHSFT, namely – i) UK Annual Conference, ii) maintaining the WSUK database, iii) WSUK website and iv) quarterly E-Newsletters.

In September 2025, WSUK held a face-to-face UK Annual Conference, which provides an important opportunity for members of the WS community to connect with each other in person and engage with WS health professionals in a non-clinic setting. In 2025, this event included i) a WS panel session involving 2 WS affected YP, who discussed their experiences of living with WS and their daily lives, and answered questions from the floor; ii) Two basic first aid sessions, which were well received by participants, when included previously in 2023, and iii) a visually impaired (VI) sports taster session delivered by the Royal National College Hereford (RNC).

Wolfram Syndrome UK

Trustees' Report

Throughout the year, WSUK has continued to regularly update the charity website (<https://wolframsyndrome.co.uk/>) to ensure that it provides the WS community with accurate, current and family-friendly information on WS-related issues, which is medically endorsed. In addition, WSUK has continued to deliver quarterly e-newsletters to all those in the WS community and its supporters who elect to receive regular updates. Each newsletter includes information on a range of topics for example, updates on the latest research, including the results of the TREATWolfram clinical trial. Each newsletter is distributed by email, uploaded on the WSUK website, and shared via WSUK social media. To help ensure the e-newsletter is as accessible as possible, visually impaired (VI) members who use a screen reader receive a text alternative for any included images. In addition, an audio version is made available through the WSUK website and on social media, and a large font printed copy is posted to a small number of members, where specifically requested.

2. Focused support for WS affected adults.

During 2025/2026, the WSUK Adult Support Co-ordinator (ASC) continued to engage with the WS affected adult community to provide on-going, focused support through activities such as: -

i. Attendance at the WS Adult MDT clinics at Queen Elizabeth Hospital (QEH).

During 2025/2026, the ASC attended five WS MDT clinics at QEH (83%) and met a total of 29 WS affected adults and their family members in person to better understand their current situation, any challenges, and on-going support needs.

ii. On-going front-line support

In addition to the WS MDT clinics, during 2025/2026, the ASC developed strong connections with many WS affected adults and family members. The ASC provided expertise and practical advice on a wide range of support activities, including, but not limited to: - emotional wellbeing support calls, adult social care referrals, MDT meetings with external stakeholders, housing issues, benefit queries, and clinical and medical queries. This included some limited in-person home or local visits, where the ASC was unable to provide effective support to the WS affected adult virtually.

Research

1. TREATWolfram clinical trial

A total of 63 children, young people and adults were recruited to the TREATWolfram clinical trial across the UK and at three other international sites in France, Spain and Poland. WSUK has previously provided funds to this trial to help support patient visit costs for UK participants. The final trial patients completed their last study visits in October 2024. The results were announced to the global WS community in June 2025, and presentations on the next steps were held at the WSUK Annual conference in September and at a global virtual conference in November.

2. WSUK Scientific Advisory Board

Following a discussion by the WSUK SAB, in July 2025 the first instalment of £9,000, from a £12,000 WSUK grant funding award, was paid to a research project in Montpellier University, France. The final instalment will be released during the 2026/2027 WSUK financial year.

3 WS International Research Symposium

In June 2025, the 10th WS International Researchers Symposium was held in Paris organised by the French WS Association. The 11th WS International Researchers Symposium will be co-hosted by WSUK and The Snow Foundation in June 2026, the next WSUK financial year.

Wolfram Syndrome UK

Trustees' Report

Fundraising

Consistent with previous years, fundraising activities were conducted throughout the year by the WSUK team, the WS community and its supporters. Specific examples include, but are not limited to: -

i. Monthly donations –

Members of the WS community and WSUK supporters continued with their regular monthly donations, which were greatly received and hugely appreciated.

ii. Local fundraising events by WSUK supporters –

Examples include: -For the third year, a local recruitment company hosted a charity football match and a 6-a-side tournament with 12 teams during the year. WSUK continued to attend each event to support the players, raise the awareness of WS and highlight how their donations help this community.

iii. Community donations –

Throughout the year, members of the WS community completed fundraising activities or made donations to help support the charity. Examples include: - a golf day organised by the grandparents of a WS affected young boy; Eton Dorney long swim marathon.

iv. Annual Golf Day event –

The 12th WSUK Annual Golf Day was held in July 2025. The participating teams, many of whom have been involved in previous events, again raised a substantial amount of funds for the charity, which is greatly appreciated.

v. Walk a week for Wolfram community challenge –

For the month of October 2025, to coincide with the WS Global Awareness Day on 1st October, a sponsored 'Walk a Week for Wolfram' challenge was organised by one of the FSCs to involve as many of the WS community and WSUK team as possible to help raise funds for the charity and awareness of the condition. This inaugural event was very successful and raised considerable funds for WSUK. As a result, this event will be held again in October 2026.

vi. Sale of UK branded items –

Similar with previous years, items such as Christmas cards, water bottles and pens were sold through both the WSUK website and social media accounts, conference and at charity fundraising events.

vii. Challenges -

In May 2025, the younger sister of a WS affected member ran a 50KM coastline ultra-marathon, and a niece of WSUK Trustee & co-founder, Paul Lynch, took part in her first Hyrox Competition at Wembley. The aunt of a late WS affected member took part in the Big Half in London in September 2025.

WSUK thanks everyone in the WS community and its supporters for their continued support in helping the charity to raise funds to deliver its important work.



WS Global Awareness Day 1st October



The fifth WS Global Awareness Day took place on October 1st, 2025. In addition to the Walk for Wolfram community challenge in the UK, WSUK and patient organisations in other countries shared posts on social media and held events to highlight awareness of WS. For example, in Spain, the public buildings were lit up in green in the hometown of a member of their WS community.

Wolfram Syndrome UK

Trustees' Report



Financial review

Policy on reserves

The trustees have examined the charity's requirements for reserves in light of the main risks to the organisation. The trustees consider that the present level of funding will be adequate to support the continuation of the charity and for it to fulfil its obligations.

At the year-end there were unrestricted reserves of £41,329 (2025: £28,508) this covers yearly running costs.

Investment policy and objectives

The objects of the company authorises it to invest and deal with moneys not immediately required for its purposes in and upon such investments securities and property as may be thought fit.

Going concern

The charity has reviewed its financial performance and general reserves position. The charity has adequate financial resources and is able to manage its business risks. The charity's planning process has taken into consideration the current economic climate and its potential impact on the various sources of income and planned expenditure.

Taking into account all factors the charity has reasonable expectation that it has adequate resources to continue in operational existence for the foreseeable future and believe that there are no material uncertainties that call into the charity's ability to continue in operation.

Accordingly, the accounts have been prepared on the basis that the charity is a going concern.

Structure, governance and management

Nature of governing document

Wolfram Syndrome UK is a Charitable Incorporated Organisation registered on 17 June 2013 with the Charity Commission of England and Wales (no. 1152445). The charity's working name is WSUK.

Wolfram Syndrome UK

Trustees' Report

Trustees

Mr A Nye

Prof T Barrett

Mr P Lynch

Mr J Isherwood

Miss A Gardner

Recruitment and appointment of trustees

The Board has the power to appoint additional trustees as it considers fit to do so.

None of the trustees has any beneficial interest in the charity.

Induction and training of trustees

Potential trustees are selected on the basis of their personal qualities and the complex issues involved. A speciality linking to charity needs is also sought. New trustees are made familiar with the charity vision, operation and goals by dialogue with existing personnel and provision of minutes and other literature pertaining to charity activity.

All trustees are already familiar with the practical work of the charity. New trustees are encouraged to attend all management committee meetings. Short training sessions (if required) to familiarise new trustees with the charity and the context within which it operates are provided.

Organisational structure

The charity is organised so that the trustees meet regularly to manage its affairs. The trustees meet at least quarterly with additional meetings as required. The charity is overseen by the trustees, supported by volunteers. The organisation operates in the UK from premises in Church Road, Worthing.

Key strategic and administrative decisions are made by agreement of the trustees, and delegated as appropriate. Day to day management of the charity is delegated to the Chief Executive, Mrs Tracy Lynch.

The annual report was approved by the trustees of the charity on 26 September 2026 and signed on its behalf by:

.....
Mr J Isherwood
Chairman and trustee

Wolfram Syndrome UK

Statement of Trustees' Responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity SORP requires the trustees to prepare financial statements for each financial year. The trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the charity and of the incoming resources and application of resources, including its income and expenditure, of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping accounting records that disclose with reasonable accuracy at any time the financial position of the charity. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the trustees of the charity on 26 September 2026 and signed on its behalf by:

.....
Mr J Isherwood
Chairman and trustee

Wolfram Syndrome UK

Independent Examiner's Report to the trustees of Wolfram Syndrome UK

I report to the charity trustees on my examination of the accounts of the Charity for the year ended 28 February 2026.

Responsibilities and basis of report

As the charity's trustees you are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 ("the Charities Act") and that an independent examination is needed.

Having satisfied myself that the charity is not subject to audit under company law and is eligible for independent examination, it is my responsibility to:

- examine the accounts under section 145 of the Charities Act,
- to follow the procedures laid down in the general Directions given by the Charity Commission (under section 145(5)(b) of the Charities Act), and
- to state whether particular matters have come to my attention.

Basis of independent examiner's statement

My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a 'true and fair' view and the report is limited to those matters set out in the statement below.

Independent examiner's statement

In connection with my examination, no material matters have come to my attention which gives me cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act; or
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination.

I have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

.....
Rachel Skells BA PFP FCA
Independent Examiner

Wiston House
1 Wiston Avenue
Worthing
West Sussex
BN14 7QL

26 September 2026

Wolfram Syndrome UK

Statement of Financial Activities for the Year Ended 28 February 2026 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted £	Restricted £	Total 2026 £
Income and Endowments from:				
Donations and legacies	3	13,222	3,594	16,816
Charitable activities	4	-	72,732	72,732
Other trading activities	5	45,245	-	45,245
Investment income	6	405	-	405
Total Income		<u>58,872</u>	<u>76,326</u>	<u>135,198</u>
Expenditure on:				
Raising funds	7	(20,431)	-	(20,431)
Charitable activities	8	<u>(22,642)</u>	<u>(95,699)</u>	<u>(118,341)</u>
Total Expenditure		<u>(43,073)</u>	<u>(95,699)</u>	<u>(138,772)</u>
Net income/(expenditure)		15,799	(19,373)	(3,574)
Transfers between funds		<u>(2,978)</u>	<u>2,978</u>	<u>-</u>
Net movement in funds		12,821	(16,395)	(3,574)
Reconciliation of funds				
Total funds brought forward		<u>28,508</u>	<u>84,023</u>	<u>112,531</u>
Total funds carried forward	19	<u><u>41,329</u></u>	<u><u>67,628</u></u>	<u><u>108,957</u></u>

The notes on pages 13 to 24 form an integral part of these financial statements.

Wolfram Syndrome UK

Statement of Financial Activities for the Year Ended 28 February 2026 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

	Note	Unrestricted £	Restricted £	Total 2025 £
Income and Endowments from:				
Donations and legacies	3	9,091	644	9,735
Charitable activities	4	-	72,307	72,307
Other trading activities	5	38,530	-	38,530
Investment income	6	-	656	656
Total Income		<u>47,621</u>	<u>73,607</u>	<u>121,228</u>
Expenditure on:				
Raising funds	7	(29,549)	-	(29,549)
Charitable activities	8	<u>(27,133)</u>	<u>(83,041)</u>	<u>(110,174)</u>
Total Expenditure		<u>(56,682)</u>	<u>(83,041)</u>	<u>(139,723)</u>
Net expenditure		<u>(9,061)</u>	<u>(9,434)</u>	<u>(18,495)</u>
Net movement in funds		(9,061)	(9,434)	(18,495)
Reconciliation of funds				
Total funds brought forward		<u>37,569</u>	<u>93,457</u>	<u>131,026</u>
Total funds carried forward	19	<u><u>28,508</u></u>	<u><u>84,023</u></u>	<u><u>112,531</u></u>

All of the charity's activities derive from continuing operations during the above two periods.

The funds breakdown for 2025 is shown in note 19.

Wolfram Syndrome UK

Balance Sheet as at 28 February 2026

	Note	2026 £	2025 £
Fixed assets			
Tangible assets	15	75	231
Current assets			
Stocks	16	848	967
Debtors	17	405	267
Cash at bank and in hand		110,279	114,891
		111,532	116,125
Creditors: Amounts falling due within one year	18	(2,650)	(3,825)
Net current assets		108,882	112,300
Net assets		108,957	112,531
Funds of the charity:			
Restricted income funds			
Restricted funds	19	67,628	84,023
Unrestricted income funds			
Unrestricted funds		41,329	28,508
Total funds	20	108,957	112,531

The financial statements on pages 10 to 24 were approved by the trustees, and authorised for issue on 26 September 2026 and signed on their behalf by:

.....
Mr J Isherwood
Chairman and Trustee

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

1 Charity status

The charity is a Charitable Incorporated Organisation (CIO) and consequently does not have share capital.

The address of its registered office is:

9 Church Way
Tarring
Worthing
West Sussex
BN13 1HD

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

Wolfram Syndrome UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The financial statements are presented in sterling and amounts rounded to the nearest £.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity.

Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis which is reasonable, justifiable and consistent.

Raising funds

These are costs incurred in attracting voluntary income and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the charity's compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Tangible fixed assets

Individual fixed assets are initially recorded at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

Depreciation and amortisation

Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows:

Asset class	Depreciation method and rate
Plant and machinery	over 4 years
Office equipment	between 2 and 5 years

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

Stock

Stock is valued at the lower of cost and net realisable value.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and cash on deposit.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Designated funds are unrestricted funds earmarked by the trustees for particular future project or commitment.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

3 Income from donations and legacies

	Unrestricted funds General £	Restricted funds £	Total 2026 £	Total 2025 £
Donations and legacies;				
Donations from individuals	7,158	3,594	10,752	5,303
Grants, including capital grants;				
Grants from other charities	3,162	-	3,162	3,009
Regular giving and capital donations	2,902	-	2,902	1,423
	<u>13,222</u>	<u>3,594</u>	<u>16,816</u>	<u>9,735</u>

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

4 Income from charitable activities

	Restricted funds £	Total funds £
Wolfram Syndrome Community Support	<u>72,732</u>	<u>72,732</u>
Total for 2026	<u><u>72,732</u></u>	<u><u>72,732</u></u>
Total for 2025	<u><u>72,307</u></u>	<u><u>72,307</u></u>

5 Income from other trading activities

	Unrestricted funds General £	Total funds £	Total 2025 £
Trading income;			
Sales of goods and services	243	243	375
Events income;			
Other events income	<u>45,002</u>	<u>45,002</u>	<u>38,155</u>
	<u><u>45,245</u></u>	<u><u>45,245</u></u>	<u><u>38,530</u></u>

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

6 Investment income

	Unrestricted funds General £	Total 2026 £	Total 2025 £
Interest receivable and similar income; Interest receivable on bank deposits	405	405	656

7 Expenditure on raising funds

a) Costs of generating donations and legacies

	Note	Unrestricted funds General £	Total 2026 £	Total 2025 £
Allocated support costs	9	1,386	1,386	7,557

b) Costs of trading activities

	Note	Unrestricted funds General £	Total 2026 £	Total 2025 £
Costs of goods sold		309	309	383
Depreciation, amortisation and other similar costs		156	156	140
Other direct costs of activities for generating funds		18,580	18,580	21,469
		19,045	19,045	21,992

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

8 Expenditure on charitable activities

	Note	Unrestricted funds General £	Restricted funds £	Total 2026 £	Total 2025 £
Wolfram Syndrome Research		1,867	9,002	10,869	17,128
Support for WS community		16,519	81,022	97,541	82,302
Conference costs		-	5,675	5,675	5,991
Governance costs	9	4,256	-	4,256	4,753
		<u>22,642</u>	<u>95,699</u>	<u>118,341</u>	<u>110,174</u>

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

9 Analysis of governance and support costs

Raising funds expenditure

Support costs allocated to raising funds

	Administration costs £	Total 2026 £	Total 2025 £
Costs of generating donations and legacies	<u>1,386</u>	<u>1,386</u>	<u>7,557</u>

Governance costs

	Unrestricted funds General £	Total 2026 £	Total 2025 £
Independent examiner fees			
Examination of the financial statements	1,626	1,626	1,428
Professional fees	16	16	13
Other governance costs	<u>2,614</u>	<u>2,614</u>	<u>3,312</u>
	<u>4,256</u>	<u>4,256</u>	<u>4,753</u>

10 Net incoming/outgoing resources

Net outgoing resources for the year include:

	2026 £	2025 £
Depreciation of fixed assets	<u>156</u>	<u>140</u>

11 Trustees remuneration and expenses

During the year the charity made the following transactions with trustees:

Mr P Lynch

£Nil (2025: £1,580) of expenses were reimbursed to Mr P Lynch during the year.

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

12 Staff costs

The aggregate payroll costs were as follows:

	2026 £	2025 £
Staff costs during the year were:		
Wages and salaries	92,751	78,217
Pension costs	3,204	2,347
	<u>95,955</u>	<u>80,564</u>

The monthly average number of persons (including senior management / leadership team) employed by the charity during the year expressed as full time equivalents was as follows:

	2026 No	2025 No
Full time employees	<u>4</u>	<u>4</u>

Contributions to the employee pension schemes for the year totalled £3,204 (2025 - £2,347).

No employee received emoluments of more than £60,000 during the year.

13 Independent examiner's remuneration

	2026 £	2025 £
Other fees to examiners		
The examining of the accounts of the charity	<u>1,626</u>	<u>1,428</u>

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

14 Taxation

The charity is a registered charity and is therefore exempt from taxation.

15 Tangible fixed assets

	Furniture and equipment £	Total £
Cost		
At 1 March 2025	4,862	4,862
At 28 February 2026	4,862	4,862
Depreciation		
At 1 March 2025	4,631	4,631
Charge for the year	156	156
At 28 February 2026	4,787	4,787
Net book value		
At 28 February 2026	75	75
At 28 February 2025	231	231

16 Stock

	2026 £	2025 £
Stocks	848	967

17 Debtors

	2026 £	2025 £
Prepayments	405	267

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

18 Creditors: amounts falling due within one year

	2026 £	2025 £
Trade creditors	84	1,620
Other taxation and social security	539	546
Accruals	1,590	1,659
	<u>2,213</u>	<u>3,825</u>

19 Funds

	Balance at 1 March 2025 £	Incoming resources £	Resources expended £	Transfers £	Balance at 28 February 2026 £
Unrestricted funds					
<i>General</i>					
General Funds	23,508	58,873	(43,074)	(7,118)	32,189
<i>Designated</i>					
Wolfram Syndrome Conference	-	-	-	4,140	4,140
Research Fund	5,000	-	-	-	5,000
	<u>5,000</u>	<u>-</u>	<u>-</u>	<u>4,140</u>	<u>9,140</u>
Total unrestricted funds	<u>28,508</u>	<u>58,873</u>	<u>(43,074)</u>	<u>(2,978)</u>	<u>41,329</u>
Restricted funds					
Wolfram Syndrome Conference	16	2,681	(5,675)	2,978	-
Research Fund	18,893	913	(9,003)	-	10,803
BCH NHS Contract	55,020	72,732	(81,021)	-	46,731
TREATWolfram	10,094	-	-	-	10,094
	<u>84,023</u>	<u>76,326</u>	<u>(95,699)</u>	<u>2,978</u>	<u>67,628</u>
Total restricted funds	<u>84,023</u>	<u>76,326</u>	<u>(95,699)</u>	<u>2,978</u>	<u>67,628</u>
Total funds	<u>112,531</u>	<u>135,199</u>	<u>(138,773)</u>	<u>-</u>	<u>108,957</u>

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

	Balance at 1 March 2024 £	Incoming resources £	Resources expended £	Balance at 28 February 2025 £
Unrestricted funds				
<i>General</i>				
General Funds	32,569	47,622	(56,683)	23,508
<i>Designated</i>				
Research Fund	5,000	-	-	5,000
Total unrestricted funds	37,569	47,622	(56,683)	28,508
Restricted				
Wolfram Syndrome Conference	6,006	-	(5,991)	15
Research Fund	34,488	1,300	(16,894)	18,894
BCH NHS Contract	42,869	72,307	(60,156)	55,020
TREATWolfram	10,094	-	-	10,094
Total restricted funds	93,457	73,607	(83,041)	84,023
Total funds	131,026	121,229	(139,724)	112,531

The specific purposes for which the funds are to be applied are as follows:

Wolfram Syndrome Conference
Income and costs towards the annual conferences.

Research Fund - Funds raised, donated or designated by WSUK to assist in research of the syndrome.

BCH NHS Contract - Provision of WS related support services to Birmingham Children's Hospital.

TREATWolfram - Funds raised, donated or designated by WSUK to assist families/individuals in covering any travel/accommodation costs that are incurred by them for taking part in the 3 year TREATWolfram clinical trial which started recruitment in January 2019, with regular visits to Birmingham Children's Hospital & Queen Elizabeth Hospital Birmingham.

During the year £7,000 was designated to conference costs, part of these funds were used to clear the negative restricted balances, at the year-end - £4,140 remained in designated. The funds were transferred from unrestricted balances.

Wolfram Syndrome UK

Notes to the Financial Statements for the Year Ended 28 February 2026

20 Analysis of net assets between funds

	Unrestricted funds General £	Restricted funds £	Total funds at 28 February 2026 £
Tangible fixed assets	75	-	75
Current assets	43,904	67,628	111,532
Current liabilities	(2,650)	-	(2,650)
Total net assets	<u>41,329</u>	<u>67,628</u>	<u>108,957</u>
	Unrestricted funds General £	Restricted funds £	Total funds at 28 February 2025 £
Tangible fixed assets	231	-	231
Current assets	32,102	84,023	116,125
Current liabilities	(3,825)	-	(3,825)
Total net assets	<u>28,508</u>	<u>84,023</u>	<u>112,531</u>

21 Related party transactions

Two employees of the charity are related to two of the trustees and their gross wages were £43,903 (2025: £39,903).